Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Enrico Bentivegna, Michelangelo Luciani, Valeria Ferrari, Silvia Galastri, Francesco Baldari, Francesco Scarso, Piera A. Lamberti & Paolo Martelletti. (2022) Recently approved and emerging drug options for migraine prophylaxis. Expert Opinion on Pharmacotherapy 23:11, pages 1325-1335.
Read now
Read now
Articles from other publishers (10)
Dong Song, Piaoyi Li, Yonggang Wang & Jin Cao. (2023) Noninvasive vagus nerve stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Neurology 14.
Crossref
Crossref
Xinyu Tao, Zeya Yan, Jiahao Meng, Wei Wang, Qiling Dai, Qiufeng Zhou, Zhifeng Wang & Zhong Wang. (2022) The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. The Journal of Headache and Pain 23:1.
Crossref
Crossref
Jason J Sico, Franz Macedo, Jeffrey Lewis, Christopher Spevak, Rebecca Vogsland, Aven Ford, Karen Skop & James Sall. (2022) The Primary Care Management of Headache: Synopsis of the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Military Medicine 187:9-10, pages e1091-e1102.
Crossref
Crossref
Peter McAllister, Lois Lamerato, Lynda J. Krasenbaum, Joshua M. Cohen, Krishna Tangirala, Stephen Thompson, Maurice Driessen, Julian Casciano, Zenobia Dotiwala & Alexander Mauskop. (2021) Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. The Journal of Headache and Pain 22:1.
Crossref
Crossref
Messoud Ashina, Joshua M. Cohen, Maja Galic, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Yoel Kessler, Lindsay Janka & Hans-Christoph Diener. (2021) Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. The Journal of Headache and Pain 22:1.
Crossref
Crossref
Egilius L. H. Spierings, Xiaoping Ning, Verena Ramirez Campos, Joshua M. Cohen, Steve Barash & Dawn C. Buse. (2021) Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study. Headache: The Journal of Head and Face Pain 61:9, pages 1376-1386.
Crossref
Crossref
К.В. Благочинная & А.В. Борисов. (2021) Innovative Technologies in Preventive Migraine Therapy. Неврология и нейрохирургия. Восточная Европа:2, pages 199-210.
Crossref
Crossref
Deborah I. Friedman & Joshua M. Cohen. (2020) Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine. Emerging Topics in Life Sciences 4:2, pages 179-190.
Crossref
Crossref
Ivan Urits, Gavin Clark, Daniel An, Bredan Wesp, Rebecca Zhou, Ariunzaya Amgalan, Amnon A. Berger, Hisham Kassem, Anh L. Ngo, Alan D. Kaye, Rachel J. Kaye, Elyse M. Cornett & Omar Viswanath. (2020) An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain and Therapy 9:1, pages 195-215.
Crossref
Crossref
Salvo Lombardo, Emanuela Mazzon, Maria Basile, Eugenio Cavalli, Placido Bramanti, Riccardo Nania, Paolo Fagone, Ferdinando Nicoletti & Maria Petralia. (2019) Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine. Brain Sciences 9:7, pages 172.
Crossref
Crossref